Your fact-checks will appear here
The ongoing clinical trials for ivermectin in cancer treatment, including the Phase I/II trial combining ivermectin with PD-1–directed immunotherapy.
Laboratory studies identify ivermectin as a host‑directed antiviral in cell cultures—most notably by disrupting importin (IMP) α/β1–mediated nuclear transport of viral proteins—producing dose‑dependen...
There is evidence of a small number of early‑phase clinical trials testing ivermectin in cancer patients, but they are limited in number, mostly based in the United States, and focused on combination ...
Short-term side effects after a standard dose of ivermectin are usually mild and transient—most commonly itch, rash, fever, headache and gastrointestinal upset within the first few days following trea...
Ivermectin shows antiviral activity in laboratory cell cultures against SARS‑CoV‑2, but large, high‑quality clinical trials and systematic reviews have not demonstrated consistent benefit for treating...